Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of monthly CAM2032 versus Eligard in prostate cancer
2014-001074-34Phase 2Completed
- Sponsor
- Camurus
- Start
- Apr 2014
- Modality
- Small Molecules, Peptides, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of CAM2032, leuprolide in prostate cancer (PCa), sponsored by Camurus. Started Apr 2014; status: completed.
02
Drugs
CAM2032leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-001074-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001074-34.